Argenica Therapeutics Limited
Argenica Therapeutics Limited (AGN.AX) Stock Competitors & Peer Comparison
See (AGN.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AGN.AX | A$0.15 | +0.00% | 18.6M | -1.81 | -A$0.08 | N/A |
| CSL.AX | A$96.22 | -1.78% | 46.1B | 11.15 | A$8.63 | +4.35% |
| TLX.AX | A$14.26 | -3.13% | 4.8B | -475.33 | -A$0.03 | N/A |
| MSB.AX | A$2.04 | -3.32% | 2.6B | -20.40 | -A$0.10 | N/A |
| NEU.AX | A$12.35 | -3.44% | 1.6B | 53.70 | A$0.23 | N/A |
| CU6.AX | A$2.60 | -10.34% | 967.9M | -9.29 | -A$0.28 | N/A |
| OPT.AX | A$0.60 | +0.00% | 820.8M | -1.40 | -A$0.43 | N/A |
| PYC.AX | A$1.33 | -6.99% | 772.5M | -16.56 | -A$0.08 | N/A |
| RAC.AX | A$2.61 | -5.43% | 488.3M | -52.20 | -A$0.05 | N/A |
| CUV.AX | A$9.13 | -3.59% | 460.3M | 14.27 | A$0.64 | +0.53% |
Stock Comparison
AGN.AX vs CSL.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, CSL.AX has a market cap of 46.1B. Regarding current trading prices, AGN.AX is priced at A$0.15, while CSL.AX trades at A$96.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas CSL.AX's P/E ratio is 11.15. In terms of profitability, AGN.AX's ROE is -1.84%, compared to CSL.AX's ROE of +0.08%. Regarding short-term risk, AGN.AX is less volatile compared to CSL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check CSL.AX's competition here
AGN.AX vs TLX.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, TLX.AX has a market cap of 4.8B. Regarding current trading prices, AGN.AX is priced at A$0.15, while TLX.AX trades at A$14.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas TLX.AX's P/E ratio is -475.33. In terms of profitability, AGN.AX's ROE is -1.84%, compared to TLX.AX's ROE of -0.02%. Regarding short-term risk, AGN.AX is less volatile compared to TLX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check TLX.AX's competition here
AGN.AX vs MSB.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, MSB.AX has a market cap of 2.6B. Regarding current trading prices, AGN.AX is priced at A$0.15, while MSB.AX trades at A$2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas MSB.AX's P/E ratio is -20.40. In terms of profitability, AGN.AX's ROE is -1.84%, compared to MSB.AX's ROE of -0.14%. Regarding short-term risk, AGN.AX is less volatile compared to MSB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check MSB.AX's competition here
AGN.AX vs NEU.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, NEU.AX has a market cap of 1.6B. Regarding current trading prices, AGN.AX is priced at A$0.15, while NEU.AX trades at A$12.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas NEU.AX's P/E ratio is 53.70. In terms of profitability, AGN.AX's ROE is -1.84%, compared to NEU.AX's ROE of +0.09%. Regarding short-term risk, AGN.AX is less volatile compared to NEU.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check NEU.AX's competition here
AGN.AX vs CU6.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, CU6.AX has a market cap of 967.9M. Regarding current trading prices, AGN.AX is priced at A$0.15, while CU6.AX trades at A$2.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas CU6.AX's P/E ratio is -9.29. In terms of profitability, AGN.AX's ROE is -1.84%, compared to CU6.AX's ROE of -0.60%. Regarding short-term risk, AGN.AX is less volatile compared to CU6.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check CU6.AX's competition here
AGN.AX vs OPT.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, OPT.AX has a market cap of 820.8M. Regarding current trading prices, AGN.AX is priced at A$0.15, while OPT.AX trades at A$0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas OPT.AX's P/E ratio is -1.40. In terms of profitability, AGN.AX's ROE is -1.84%, compared to OPT.AX's ROE of +1.32%. Regarding short-term risk, AGN.AX is less volatile compared to OPT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check OPT.AX's competition here
AGN.AX vs PYC.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, PYC.AX has a market cap of 772.5M. Regarding current trading prices, AGN.AX is priced at A$0.15, while PYC.AX trades at A$1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas PYC.AX's P/E ratio is -16.56. In terms of profitability, AGN.AX's ROE is -1.84%, compared to PYC.AX's ROE of -0.30%. Regarding short-term risk, AGN.AX is less volatile compared to PYC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check PYC.AX's competition here
AGN.AX vs RAC.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, RAC.AX has a market cap of 488.3M. Regarding current trading prices, AGN.AX is priced at A$0.15, while RAC.AX trades at A$2.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas RAC.AX's P/E ratio is -52.20. In terms of profitability, AGN.AX's ROE is -1.84%, compared to RAC.AX's ROE of -0.47%. Regarding short-term risk, AGN.AX is less volatile compared to RAC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check RAC.AX's competition here
AGN.AX vs CUV.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, CUV.AX has a market cap of 460.3M. Regarding current trading prices, AGN.AX is priced at A$0.15, while CUV.AX trades at A$9.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas CUV.AX's P/E ratio is 14.27. In terms of profitability, AGN.AX's ROE is -1.84%, compared to CUV.AX's ROE of +0.13%. Regarding short-term risk, AGN.AX is less volatile compared to CUV.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check CUV.AX's competition here
AGN.AX vs SPL.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, SPL.AX has a market cap of 231.5M. Regarding current trading prices, AGN.AX is priced at A$0.15, while SPL.AX trades at A$0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas SPL.AX's P/E ratio is -55.00. In terms of profitability, AGN.AX's ROE is -1.84%, compared to SPL.AX's ROE of -0.16%. Regarding short-term risk, AGN.AX is less volatile compared to SPL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check SPL.AX's competition here
AGN.AX vs OCC.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, OCC.AX has a market cap of 182.1M. Regarding current trading prices, AGN.AX is priced at A$0.15, while OCC.AX trades at A$0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas OCC.AX's P/E ratio is -16.40. In terms of profitability, AGN.AX's ROE is -1.84%, compared to OCC.AX's ROE of -0.45%. Regarding short-term risk, AGN.AX is less volatile compared to OCC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check OCC.AX's competition here
AGN.AX vs RCE.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, RCE.AX has a market cap of 135.9M. Regarding current trading prices, AGN.AX is priced at A$0.15, while RCE.AX trades at A$0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas RCE.AX's P/E ratio is -4.27. In terms of profitability, AGN.AX's ROE is -1.84%, compared to RCE.AX's ROE of +2.79%. Regarding short-term risk, AGN.AX is less volatile compared to RCE.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check RCE.AX's competition here
AGN.AX vs ACW.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, ACW.AX has a market cap of 129.2M. Regarding current trading prices, AGN.AX is priced at A$0.15, while ACW.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas ACW.AX's P/E ratio is -3.60. In terms of profitability, AGN.AX's ROE is -1.84%, compared to ACW.AX's ROE of -1.34%. Regarding short-term risk, AGN.AX is less volatile compared to ACW.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check ACW.AX's competition here
AGN.AX vs DXB.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, DXB.AX has a market cap of 126.1M. Regarding current trading prices, AGN.AX is priced at A$0.15, while DXB.AX trades at A$0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas DXB.AX's P/E ratio is -7.00. In terms of profitability, AGN.AX's ROE is -1.84%, compared to DXB.AX's ROE of -2.79%. Regarding short-term risk, AGN.AX is less volatile compared to DXB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check DXB.AX's competition here
AGN.AX vs PAA.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, PAA.AX has a market cap of 111.9M. Regarding current trading prices, AGN.AX is priced at A$0.15, while PAA.AX trades at A$0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas PAA.AX's P/E ratio is -11.50. In terms of profitability, AGN.AX's ROE is -1.84%, compared to PAA.AX's ROE of -1.28%. Regarding short-term risk, AGN.AX is less volatile compared to PAA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check PAA.AX's competition here
AGN.AX vs ATH.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, ATH.AX has a market cap of 108.8M. Regarding current trading prices, AGN.AX is priced at A$0.15, while ATH.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas ATH.AX's P/E ratio is -1.00. In terms of profitability, AGN.AX's ROE is -1.84%, compared to ATH.AX's ROE of -0.30%. Regarding short-term risk, AGN.AX is less volatile compared to ATH.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check ATH.AX's competition here
AGN.AX vs NYR.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, NYR.AX has a market cap of 107.9M. Regarding current trading prices, AGN.AX is priced at A$0.15, while NYR.AX trades at A$0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas NYR.AX's P/E ratio is -27.00. In terms of profitability, AGN.AX's ROE is -1.84%, compared to NYR.AX's ROE of -0.83%. Regarding short-term risk, AGN.AX is less volatile compared to NYR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check NYR.AX's competition here
AGN.AX vs ILA.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, ILA.AX has a market cap of 106.3M. Regarding current trading prices, AGN.AX is priced at A$0.15, while ILA.AX trades at A$0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas ILA.AX's P/E ratio is -14.17. In terms of profitability, AGN.AX's ROE is -1.84%, compared to ILA.AX's ROE of -1.01%. Regarding short-term risk, AGN.AX is less volatile compared to ILA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check ILA.AX's competition here
AGN.AX vs ALA.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, ALA.AX has a market cap of 90.7M. Regarding current trading prices, AGN.AX is priced at A$0.15, while ALA.AX trades at A$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas ALA.AX's P/E ratio is -7.50. In terms of profitability, AGN.AX's ROE is -1.84%, compared to ALA.AX's ROE of -0.41%. Regarding short-term risk, AGN.AX is less volatile compared to ALA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check ALA.AX's competition here
AGN.AX vs IMM.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, IMM.AX has a market cap of 89.9M. Regarding current trading prices, AGN.AX is priced at A$0.15, while IMM.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas IMM.AX's P/E ratio is -1.22. In terms of profitability, AGN.AX's ROE is -1.84%, compared to IMM.AX's ROE of -0.69%. Regarding short-term risk, AGN.AX is less volatile compared to IMM.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check IMM.AX's competition here
AGN.AX vs PAR.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, PAR.AX has a market cap of 73.7M. Regarding current trading prices, AGN.AX is priced at A$0.15, while PAR.AX trades at A$0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas PAR.AX's P/E ratio is -1.70. In terms of profitability, AGN.AX's ROE is -1.84%, compared to PAR.AX's ROE of -2.66%. Regarding short-term risk, AGN.AX is less volatile compared to PAR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check PAR.AX's competition here
AGN.AX vs ATX.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, ATX.AX has a market cap of 71.8M. Regarding current trading prices, AGN.AX is priced at A$0.15, while ATX.AX trades at A$0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas ATX.AX's P/E ratio is -7.00. In terms of profitability, AGN.AX's ROE is -1.84%, compared to ATX.AX's ROE of -0.25%. Regarding short-term risk, AGN.AX is less volatile compared to ATX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check ATX.AX's competition here
AGN.AX vs CYP.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, CYP.AX has a market cap of 70.6M. Regarding current trading prices, AGN.AX is priced at A$0.15, while CYP.AX trades at A$0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas CYP.AX's P/E ratio is -7.25. In terms of profitability, AGN.AX's ROE is -1.84%, compared to CYP.AX's ROE of -1.79%. Regarding short-term risk, AGN.AX is less volatile compared to CYP.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check CYP.AX's competition here
AGN.AX vs PTX.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, PTX.AX has a market cap of 70.5M. Regarding current trading prices, AGN.AX is priced at A$0.15, while PTX.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas PTX.AX's P/E ratio is -6.70. In terms of profitability, AGN.AX's ROE is -1.84%, compared to PTX.AX's ROE of -0.62%. Regarding short-term risk, AGN.AX is less volatile compared to PTX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check PTX.AX's competition here
AGN.AX vs ENP.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, ENP.AX has a market cap of 62M. Regarding current trading prices, AGN.AX is priced at A$0.15, while ENP.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas ENP.AX's P/E ratio is N/A. In terms of profitability, AGN.AX's ROE is -1.84%, compared to ENP.AX's ROE of -1.05%. Regarding short-term risk, AGN.AX is less volatile compared to ENP.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check ENP.AX's competition here
AGN.AX vs BIO.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, BIO.AX has a market cap of 58.1M. Regarding current trading prices, AGN.AX is priced at A$0.15, while BIO.AX trades at A$0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas BIO.AX's P/E ratio is -25.50. In terms of profitability, AGN.AX's ROE is -1.84%, compared to BIO.AX's ROE of +0.18%. Regarding short-term risk, AGN.AX is less volatile compared to BIO.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check BIO.AX's competition here
AGN.AX vs BOT.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, BOT.AX has a market cap of 53.8M. Regarding current trading prices, AGN.AX is priced at A$0.15, while BOT.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas BOT.AX's P/E ratio is -0.54. In terms of profitability, AGN.AX's ROE is -1.84%, compared to BOT.AX's ROE of -1.31%. Regarding short-term risk, AGN.AX is less volatile compared to BOT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check BOT.AX's competition here
AGN.AX vs NUZ.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, NUZ.AX has a market cap of 52.2M. Regarding current trading prices, AGN.AX is priced at A$0.15, while NUZ.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas NUZ.AX's P/E ratio is -2.33. In terms of profitability, AGN.AX's ROE is -1.84%, compared to NUZ.AX's ROE of -2.54%. Regarding short-term risk, AGN.AX is less volatile compared to NUZ.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check NUZ.AX's competition here
AGN.AX vs RAD.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, RAD.AX has a market cap of 47.3M. Regarding current trading prices, AGN.AX is priced at A$0.15, while RAD.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas RAD.AX's P/E ratio is -1.00. In terms of profitability, AGN.AX's ROE is -1.84%, compared to RAD.AX's ROE of -0.93%. Regarding short-term risk, AGN.AX is less volatile compared to RAD.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check RAD.AX's competition here
AGN.AX vs AVE.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, AVE.AX has a market cap of 38.6M. Regarding current trading prices, AGN.AX is priced at A$0.15, while AVE.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas AVE.AX's P/E ratio is N/A. In terms of profitability, AGN.AX's ROE is -1.84%, compared to AVE.AX's ROE of -2.58%. Regarding short-term risk, AGN.AX and AVE.AX have similar daily volatility (0.00).Check AVE.AX's competition here
AGN.AX vs IMU.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, IMU.AX has a market cap of 37.8M. Regarding current trading prices, AGN.AX is priced at A$0.15, while IMU.AX trades at A$0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas IMU.AX's P/E ratio is -0.40. In terms of profitability, AGN.AX's ROE is -1.84%, compared to IMU.AX's ROE of -1.35%. Regarding short-term risk, AGN.AX is less volatile compared to IMU.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check IMU.AX's competition here
AGN.AX vs NSB.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, NSB.AX has a market cap of 33.3M. Regarding current trading prices, AGN.AX is priced at A$0.15, while NSB.AX trades at A$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas NSB.AX's P/E ratio is -5.00. In terms of profitability, AGN.AX's ROE is -1.84%, compared to NSB.AX's ROE of -0.19%. Regarding short-term risk, AGN.AX is less volatile compared to NSB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check NSB.AX's competition here
AGN.AX vs ADO.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, ADO.AX has a market cap of 32.7M. Regarding current trading prices, AGN.AX is priced at A$0.15, while ADO.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas ADO.AX's P/E ratio is -1.10. In terms of profitability, AGN.AX's ROE is -1.84%, compared to ADO.AX's ROE of -1.42%. Regarding short-term risk, AGN.AX is less volatile compared to ADO.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check ADO.AX's competition here
AGN.AX vs EZZ.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, EZZ.AX has a market cap of 29.4M. Regarding current trading prices, AGN.AX is priced at A$0.15, while EZZ.AX trades at A$0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas EZZ.AX's P/E ratio is 10.42. In terms of profitability, AGN.AX's ROE is -1.84%, compared to EZZ.AX's ROE of +0.10%. Regarding short-term risk, AGN.AX is less volatile compared to EZZ.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check EZZ.AX's competition here
AGN.AX vs NC6.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, NC6.AX has a market cap of 27.4M. Regarding current trading prices, AGN.AX is priced at A$0.15, while NC6.AX trades at A$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas NC6.AX's P/E ratio is -7.80. In terms of profitability, AGN.AX's ROE is -1.84%, compared to NC6.AX's ROE of -19.65%. Regarding short-term risk, AGN.AX and NC6.AX have similar daily volatility (0.00).Check NC6.AX's competition here
AGN.AX vs PIQ.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, PIQ.AX has a market cap of 24.8M. Regarding current trading prices, AGN.AX is priced at A$0.15, while PIQ.AX trades at A$0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas PIQ.AX's P/E ratio is -2.14. In terms of profitability, AGN.AX's ROE is -1.84%, compared to PIQ.AX's ROE of -0.94%. Regarding short-term risk, AGN.AX is less volatile compared to PIQ.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check PIQ.AX's competition here
AGN.AX vs LCT.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, LCT.AX has a market cap of 24.5M. Regarding current trading prices, AGN.AX is priced at A$0.15, while LCT.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas LCT.AX's P/E ratio is N/A. In terms of profitability, AGN.AX's ROE is -1.84%, compared to LCT.AX's ROE of -0.62%. Regarding short-term risk, AGN.AX and LCT.AX have similar daily volatility (0.00).Check LCT.AX's competition here
AGN.AX vs 1AI.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, 1AI.AX has a market cap of 22.3M. Regarding current trading prices, AGN.AX is priced at A$0.15, while 1AI.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas 1AI.AX's P/E ratio is N/A. In terms of profitability, AGN.AX's ROE is -1.84%, compared to 1AI.AX's ROE of -0.49%. Regarding short-term risk, AGN.AX and 1AI.AX have similar daily volatility (0.00).Check 1AI.AX's competition here
AGN.AX vs KZA.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, KZA.AX has a market cap of 18.9M. Regarding current trading prices, AGN.AX is priced at A$0.15, while KZA.AX trades at A$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas KZA.AX's P/E ratio is -0.73. In terms of profitability, AGN.AX's ROE is -1.84%, compared to KZA.AX's ROE of -26.34%. Regarding short-term risk, AGN.AX is less volatile compared to KZA.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check KZA.AX's competition here
AGN.AX vs NOX.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, NOX.AX has a market cap of 18.4M. Regarding current trading prices, AGN.AX is priced at A$0.15, while NOX.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas NOX.AX's P/E ratio is -3.00. In terms of profitability, AGN.AX's ROE is -1.84%, compared to NOX.AX's ROE of +25.10%. Regarding short-term risk, AGN.AX and NOX.AX have similar daily volatility (0.00).Check NOX.AX's competition here
AGN.AX vs BTC.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, BTC.AX has a market cap of 17.1M. Regarding current trading prices, AGN.AX is priced at A$0.15, while BTC.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas BTC.AX's P/E ratio is 5.50. In terms of profitability, AGN.AX's ROE is -1.84%, compared to BTC.AX's ROE of -0.10%. Regarding short-term risk, AGN.AX and BTC.AX have similar daily volatility (0.00).Check BTC.AX's competition here
AGN.AX vs MDC.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, MDC.AX has a market cap of 15.1M. Regarding current trading prices, AGN.AX is priced at A$0.15, while MDC.AX trades at A$6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas MDC.AX's P/E ratio is -0.01. In terms of profitability, AGN.AX's ROE is -1.84%, compared to MDC.AX's ROE of -9.94%. Regarding short-term risk, AGN.AX and MDC.AX have similar daily volatility (0.00).Check MDC.AX's competition here
AGN.AX vs MEM.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, MEM.AX has a market cap of 14.2M. Regarding current trading prices, AGN.AX is priced at A$0.15, while MEM.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas MEM.AX's P/E ratio is N/A. In terms of profitability, AGN.AX's ROE is -1.84%, compared to MEM.AX's ROE of -0.92%. Regarding short-term risk, AGN.AX is less volatile compared to MEM.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check MEM.AX's competition here
AGN.AX vs BNO.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, BNO.AX has a market cap of 13.2M. Regarding current trading prices, AGN.AX is priced at A$0.15, while BNO.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas BNO.AX's P/E ratio is -0.45. In terms of profitability, AGN.AX's ROE is -1.84%, compared to BNO.AX's ROE of +0.47%. Regarding short-term risk, AGN.AX is less volatile compared to BNO.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check BNO.AX's competition here
AGN.AX vs PAB.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, PAB.AX has a market cap of 10.6M. Regarding current trading prices, AGN.AX is priced at A$0.15, while PAB.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas PAB.AX's P/E ratio is -1.55. In terms of profitability, AGN.AX's ROE is -1.84%, compared to PAB.AX's ROE of -4.06%. Regarding short-term risk, AGN.AX is less volatile compared to PAB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check PAB.AX's competition here
AGN.AX vs CMB.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, CMB.AX has a market cap of 9M. Regarding current trading prices, AGN.AX is priced at A$0.15, while CMB.AX trades at A$0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas CMB.AX's P/E ratio is -2.79. In terms of profitability, AGN.AX's ROE is -1.84%, compared to CMB.AX's ROE of -2.19%. Regarding short-term risk, AGN.AX is less volatile compared to CMB.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check CMB.AX's competition here
AGN.AX vs IXC.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, IXC.AX has a market cap of 8.6M. Regarding current trading prices, AGN.AX is priced at A$0.15, while IXC.AX trades at A$0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas IXC.AX's P/E ratio is -11.50. In terms of profitability, AGN.AX's ROE is -1.84%, compared to IXC.AX's ROE of -0.17%. Regarding short-term risk, AGN.AX is less volatile compared to IXC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check IXC.AX's competition here
AGN.AX vs BGT.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, BGT.AX has a market cap of 8.5M. Regarding current trading prices, AGN.AX is priced at A$0.15, while BGT.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas BGT.AX's P/E ratio is -2.80. In terms of profitability, AGN.AX's ROE is -1.84%, compared to BGT.AX's ROE of -1.40%. Regarding short-term risk, AGN.AX and BGT.AX have similar daily volatility (0.00).Check BGT.AX's competition here
AGN.AX vs IMC.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, IMC.AX has a market cap of 8.5M. Regarding current trading prices, AGN.AX is priced at A$0.15, while IMC.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas IMC.AX's P/E ratio is -1.65. In terms of profitability, AGN.AX's ROE is -1.84%, compared to IMC.AX's ROE of -0.44%. Regarding short-term risk, AGN.AX is less volatile compared to IMC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check IMC.AX's competition here
AGN.AX vs TRP.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, TRP.AX has a market cap of 7.6M. Regarding current trading prices, AGN.AX is priced at A$0.15, while TRP.AX trades at A$0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas TRP.AX's P/E ratio is -2.08. In terms of profitability, AGN.AX's ROE is -1.84%, compared to TRP.AX's ROE of -0.30%. Regarding short-term risk, AGN.AX and TRP.AX have similar daily volatility (0.00).Check TRP.AX's competition here
AGN.AX vs ZLD.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, ZLD.AX has a market cap of 5.9M. Regarding current trading prices, AGN.AX is priced at A$0.15, while ZLD.AX trades at A$0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas ZLD.AX's P/E ratio is -1.56. In terms of profitability, AGN.AX's ROE is -1.84%, compared to ZLD.AX's ROE of +0.56%. Regarding short-term risk, AGN.AX is less volatile compared to ZLD.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check ZLD.AX's competition here
AGN.AX vs VBS.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, VBS.AX has a market cap of 5.6M. Regarding current trading prices, AGN.AX is priced at A$0.15, while VBS.AX trades at A$0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas VBS.AX's P/E ratio is -3.50. In terms of profitability, AGN.AX's ROE is -1.84%, compared to VBS.AX's ROE of +2.65%. Regarding short-term risk, AGN.AX is less volatile compared to VBS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check VBS.AX's competition here
AGN.AX vs CHM.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, CHM.AX has a market cap of 5.1M. Regarding current trading prices, AGN.AX is priced at A$0.15, while CHM.AX trades at A$0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas CHM.AX's P/E ratio is -0.15. In terms of profitability, AGN.AX's ROE is -1.84%, compared to CHM.AX's ROE of +28.45%. Regarding short-term risk, AGN.AX is less volatile compared to CHM.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check CHM.AX's competition here
AGN.AX vs BIT.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, BIT.AX has a market cap of 4.1M. Regarding current trading prices, AGN.AX is priced at A$0.15, while BIT.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas BIT.AX's P/E ratio is -0.25. In terms of profitability, AGN.AX's ROE is -1.84%, compared to BIT.AX's ROE of -1.19%. Regarding short-term risk, AGN.AX is less volatile compared to BIT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check BIT.AX's competition here
AGN.AX vs ACR.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, ACR.AX has a market cap of 4.1M. Regarding current trading prices, AGN.AX is priced at A$0.15, while ACR.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas ACR.AX's P/E ratio is -1.00. In terms of profitability, AGN.AX's ROE is -1.84%, compared to ACR.AX's ROE of -2.12%. Regarding short-term risk, AGN.AX is less volatile compared to ACR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check ACR.AX's competition here
AGN.AX vs RGS.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, RGS.AX has a market cap of 3.7M. Regarding current trading prices, AGN.AX is priced at A$0.15, while RGS.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas RGS.AX's P/E ratio is -1.20. In terms of profitability, AGN.AX's ROE is -1.84%, compared to RGS.AX's ROE of +4.56%. Regarding short-term risk, AGN.AX is less volatile compared to RGS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check RGS.AX's competition here
AGN.AX vs 1AD.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, 1AD.AX has a market cap of 3M. Regarding current trading prices, AGN.AX is priced at A$0.15, while 1AD.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas 1AD.AX's P/E ratio is -0.50. In terms of profitability, AGN.AX's ROE is -1.84%, compared to 1AD.AX's ROE of +10.68%. Regarding short-term risk, AGN.AX and 1AD.AX have similar daily volatility (0.00).Check 1AD.AX's competition here
AGN.AX vs EX1.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, EX1.AX has a market cap of 1.9M. Regarding current trading prices, AGN.AX is priced at A$0.15, while EX1.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas EX1.AX's P/E ratio is -0.12. In terms of profitability, AGN.AX's ROE is -1.84%, compared to EX1.AX's ROE of -1.10%. Regarding short-term risk, AGN.AX and EX1.AX have similar daily volatility (0.00).Check EX1.AX's competition here
AGN.AX vs ANR.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, ANR.AX has a market cap of 1.9M. Regarding current trading prices, AGN.AX is priced at A$0.15, while ANR.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas ANR.AX's P/E ratio is -0.90. In terms of profitability, AGN.AX's ROE is -1.84%, compared to ANR.AX's ROE of -1.09%. Regarding short-term risk, AGN.AX is less volatile compared to ANR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for AGN.AX.Check ANR.AX's competition here
AGN.AX vs HXL.AX Comparison May 2026
AGN.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AGN.AX stands at 18.6M. In comparison, HXL.AX has a market cap of 542.9K. Regarding current trading prices, AGN.AX is priced at A$0.15, while HXL.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AGN.AX currently has a P/E ratio of -1.81, whereas HXL.AX's P/E ratio is -0.65. In terms of profitability, AGN.AX's ROE is -1.84%, compared to HXL.AX's ROE of -0.32%. Regarding short-term risk, AGN.AX and HXL.AX have similar daily volatility (0.00).Check HXL.AX's competition here